Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 289-550-2 | CAS number: 89923-62-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 was found to be greater than 2500 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- Code No.: FAT 20242/E
Batch No.: EN 1500.52
Contents of active ingredients: 100%
Validity: April 1991
Description: Solid/powder; Solubility in water: Approx. (10g/L at 20°C, pH 7.3)
Test article received: June 2, 1986. - Species:
- rat
- Strain:
- other: Albino rats, Tif: RAIf(SPF), F3-hybrid of RII 1/Tif x RII 2/Tif
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: CIBA-GEIGY LTD. Tierfarm, 4334 SIsseln, Switzerland
- Age at study initiation: 7-8 weeks
- Weight at study initiation: 172 to 203 g
- Fasting period before study: Prior to dosing, the animals were fasted overnight
- Housing: The animals were kept under conventional laboratory conditions. They were caged in groups of 5 in Macrolon cages type 4 with standardized soft wood bedding (Societe Parisienne des sciures, Pantin).
- Individual identification: By colour code using picric acid.
- Diet: Rat food, NAFAG N° 890, NAFAG AG, Gossau, SG Switzerland; ad libitum
- Water: Provided ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 3°C
- Humidity: 55 ± 15%
- Air changes: Approx. 15 air changes/h
- Photoperiod: 12 hours light/day - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Remarks:
- (Siegfried AG, Zofingen/Switzerland
- Details on oral exposure:
- VEHICLE
- Volume (ml/kg body weight) applied: 20 - Doses:
- 5000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
*Mortality: Daily; a.m. and p.m. on working day, a.m. on weekend days.
*Signs and symptoms: Daily
*Body weight: On day 1, 7 and 14
- Necropsy of survivors performed: yes, the animals were submitted to a gross necropsy at the end of the observation period. - Statistics:
- From the body weights, the group means and their standard deviations were calculated.
- Preliminary study:
- None
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality was seen.
- Clinical signs:
- other: Dyspnea, ruffled fur and curved body position, being comon symptoms in acute tests, were observed after the test item administration. The animals recovered within 12 days.
- Gross pathology:
- The animals were submitted to a gross necropsy at the end of the observation period.
- Other findings:
- None
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The LD50 for FAT 20242/E was claculated to be >5000 mg/kg bw.
- Executive summary:
A study was performed to determine the acute oral toxicity of FAT 20242/E in rats via oral route in accordance with OECD Guideline 401. Following oral administration to 5 male and 5 female albino rats at 5000 mg/kg bw, the animals were observed for mortality, clinical signs and body weights during the 14 day post-treatment observation period. No mortality was seen. Dyspnea, ruffled fur and curved body position, being comon symptoms in acute tests, were observed after the test item administration. The animals recovered within 12 days. Expected weight gain in males and females seen. No deviations from normal morphology were found at post mortem examination. Hence based on these findings, the LD50 for FAT 20242/E was concluded to be >5000 mg/kg bw.
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- High quality OECD guideline study
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral:
The study considered to be key was performed to determine the acute oral toxicity of FAT 20242/E in rats via oral route in accordance with OECD Guideline 401. Following oral administration to 5 male and 5 female albino rats at 5000 mg/kg bw, the animals were observed for mortality, clinical signs and body weights during the 14 day post-treatment observation period. No mortality was seen.Dyspnea, ruffled fur and curved body position, being comon symptoms in acute tests, were observed after the test item administration. The animals recovered within 12 days. Expected weight gain in males and females seen. No deviations from normal morphology were found at post mortem examination. Hence based on these findings, the LD50 for FAT 20242/E was concluded to be >5000 mg/kg bw.
A supporting study was carried out for the determination of the acute oral LD50 of FAT 20242/A using 80 Tif. RAI rats by following OECD TG 401. Before administration by oral intubation, FAT 20242/A was suspended in polyethylene glycol (PEG 400).The test material was administered at1000,2500, 5000 and 7000 mg/kg bw respectively. At 1000 mg/kg bw, no mortality was seen. However, 15, 55 and 50 % mortality was seen at 2500, 5000 and 7000 mg/kg bw, respectively. Sedation, dyspnoea, exophthalmos, ruffled fur, diarrhoea, body position (ventral, lateral and curved) and convulsions were the clinical signs observed. The clinical signs reversed by day 8. At necropsy,no substance related gross organ changes were seen.In conclusion, the acute oral LD50 of FAT 20242/A in rats of both sexes observed over a period of 14 days is greater than 2500 mg/kg bw.
Inhalation:
Currently no study to assess the acute inhalation toxicity potential of FAT 20242/I is available. However, the vapour pressure for the target chemical is low owing to the high melting point >300 °C, hence its considered to have low volatility. Synthesis and spray drying of this chemical is performed in a closed process; the final product consists of non-dusty granules. Hence, the use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalation route will be unlikely to occur. Further the chemical was found to have low acute toxicity when tested via oral route with no mortality and clinical signs when tested at 5000 mg/kg bw. Hence, considering all the above arguments, it is considered that FAT 20242/I has a low toxicity potential via inhalation route and thus the study on acute inhalation toxicity is considered scientifically not necessary.
Dermal:
Currently no study to assess acute dermal toxicity of FAT 20242/I is available. However, the molecular weight of the chemical is 487.45 g/mol, indicating moderate potential for dermal absorption. The chemical showed low toxicity potential in the available acute oral toxicity studies (LD50 >2000 mg/kg bw). Similarly, absence of systemic toxicity in skin irritation as well as sensitization studies, further supports the conclusion that no adverse effects are expected via the dermal route. Further experience with similar chemical substances has demonstrated that it is very unlikely that toxicity related to the intrinsic properties of the chemical only show up upon dermal exposure and not after systemic application. Hence, low toxicity is expected on acute dermal exposure of FAT 20242/I and testing by the dermal route was considered scientifically not necessary.
Justification for classification or non-classification
The acute oral LD50 of FAT 20242/A in rats of both sexes observed over a period of 14 days is greater than 2500 mg/kg bw. The test item does not meet the criteria for classification according to the Globally Harmonized Classification System.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.